Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Slightly Bullish +25

CureVac takes Moderna to court over mRNA vaccine patents - European Biotechnology Magazine

📉 CureVac has filed a federal lawsuit against Moderna alleging patent infringement over the mRNA-based COVID-19 vaccine Spikevax.

💰 The German biotech company seeks monetary damages in the form of royalties based on a share of Spikevax sales.

🧬 CureVac claims Moderna utilized its proprietary mRNA-stabilisation and delivery technologies without authorization.

⚖️ This case is part of a broader trend where companies like Bayer are pursuing revenue shares from established COVID-19 vaccine makers through patent actions.

🏗️ BioNTech, CureVac's parent company at the time of filing, previously sued Moderna regarding its next-generation mNEXSPIKE shot separately.

🛡️ Moderna has acknowledged the complaint and vowed to defend itself by stating its vaccine portfolio relies on internally developed know-how.

🚀 CureVac’s lawsuit marks an aggressive IP monetisation strategy as it leverages legacy patents acquired through BioNTech rather than relying solely on Pfizer partnerships.

🏢 BioNTech acquired CureVac (now referred to as part of the larger German biotech group) to consolidate a strong mRNA IP portfolio for litigation leverage.

💉 This legal dispute highlights the competitive intensity within the mRNA ecosystem following the multibillion-dollar success of recent vaccines.

⚡️ The Unified Patent Court is noted as a mechanism intended to facilitate such cross-border patent litigation across Europe.

Bullish Signals
  • CureVac is pursuing monetary damages framed as royalties on Moderna's Spikevax sales, indicating strong revenue upside potential from high-volume vaccine production.
  • BioNTech has strengthened its position by integrating CureVac's legacy mRNA IP portfolio with one of the most successful COVID-19 vaccine developers, enhancing leverage to enforce patents across the mRNA ecosystem.
  • The acquisition of CureVac in 2025 placed its proprietary methods for stabilising messenger RNA under the same roof as BioNTech, directly boosting the value of the Pfizer-BioNTech Comirnaty platform.
  • BioNTech has presented compelling Phase II data for its compound trastuzumab pamirtecan, advancing its pipeline beyond COVID-19 vaccines into high-value oncology treatments like advanced uterine cancer.
  • The Unified Patent Court has been established to make patent litigation in Europe easier, faster and more affordable, providing a streamlined framework for capturing value from mRNA innovation.
Risk Factors
  • CureVac has filed a federal lawsuit accusing Moderna of patent infringement over its mRNA-based COVID-19 vaccine Spikevax, seeking monetary damages framed as royalties on sales.
  • Moderna has acknowledged the complaint and stated it will defend itself vigorously, arguing that its COVID-19 vaccine portfolio is built on internally developed know-how and does not infringe CureVac's patents.
Full Analysis
CureVac has filed a federal lawsuit accusing Moderna of patent infringement regarding its mRNA-based COVID-19 vaccine, Spikevax. The German biotech company claims that Moderna utilized its proprietary methods for stabilizing messenger RNA without authorization and is seeking monetary damages structured as royalties on Spikevax sales. CureVac argues that it developed the specific mRNA-stabilization and delivery technologies at its Tübingen-based facility, which are central to the efficacy and manufacturability of Moderna's vaccine. By asserting several patents covering these methods, CureVac aims to capture a share of the multibillion-dollar returns generated by mRNA-based COVID-19 vaccines. This legal action follows a broader trend in the biotech sector where numerous companies have attempted to secure a portion of the revenue from COVID-19 vaccines after their development. Earlier this year, Bayer launched a broad patent offensive against makers of mRNA vaccines, and BioNTech, which acquired CureVac in 2025, filed a separate U.S. patent action against Moderna concerning its next-generation mNEXSPIKE shot. This current lawsuit is notable because it asserts CureVac's own legacy patents rather than relying on the Pfizer-BioNTech partnership structure, signaling a more aggressive stance on intellectual property monetisation. The acquisition of CureVac by BioNTech has placed its legacy mRNA IP portfolio under the same corporate roof as one of the most successful COVID-19 vaccine developers, providing stronger leverage to enforce patents across the mRNA ecosystem. In response to the complaint, Moderna has acknowledged the filing and stated it will defend itself vigorously. The pharmaceutical giant argues that its COVID-19 vaccine portfolio is built on internally developed know-how and does not infringe upon CureVac's patents. CureVac, best known for its early work on mRNA vaccines and cancer-immunotherapy platforms, is positioning this case as a significant move to capitalize on the financial success of the pandemic-era technology boom. The Unified Patent Court and the unitary patent have also been established to make patent litigation in Europe easier, faster, and more affordable, which may influence how such disputes are adjudicated moving forward. Contextual developments in the biotech sector include BioNTech's presentation of compelling Phase II data for its compound trastuzumab pamirtecan in patients with advanced uterine cancer and Swiss biotech company Anaveon appointing a new Chief Executive Officer, Thaminda Ramanayake, in March. These industry movements occur against the backdrop of intensified patent disputes aimed at capturing value from established therapeutic platforms.